Diabetic Retinopathy in Italy: Epidemiology Data and

Telemedicine Screening Programs by Vujosevic, Stela & Midena, Edoardo
Review Article
Diabetic Retinopathy in Italy: Epidemiology Data and
Telemedicine Screening Programs
Stela Vujosevic1 and EdoardoMidena1,2
1Department of Ophthalmology, University of Padova, Padova, Italy
2Fondazione G. B. Bietti, IRCCS, Roma, Italy
Correspondence should be addressed to Stela Vujosevic; stela.vujosevic@unipd.it
Received 8 September 2016; Revised 26 October 2016; Accepted 30 October 2016
Academic Editor: Goran Petrovski
Copyright © 2016 S. Vujosevic and E. Midena. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
In Italy, the number of people living with diabetes is about 3.5 million (5.5% of the population), with an increase by about 60% in
the last 20 years and with 1 person out of 3 older than 65 years. The Italian Health Service system estimates that 10 billion euros is
spent annually on caring for patients with diabetes, a figure that increases yearly. No national data on prevalence and incidence of
legal blindness in patients with diabetes and no national registry of patients with diabetic retinopathy (DR) are currently available.
However, the available epidemiological data (in several locations throughout the country) are consistent with those reported in
other European countries. The use of telemedicine for the screening of DR in Italy is confined to geographically limited locations.
The available data in the literature on implementation and use of telematic screening proved to be successful from patient, caregiver,
and authorities point of view. This review addresses the available epidemiological data on DR and telematic screening realities in
Italy and thus may help in establishing a national screening program.
1. Diabetes Mellitus: The Italian Scenario
Diabetes mellitus (DM) is considered a global epidemic of
the 21st century with currently 382 million people affected
worldwide and with a projection of doubling this number
(592 million) by 2035, as estimated by the World Health
Organization [1]. In Italy, the number of patients withDMhas
increased by about 60% in the last 20 years, from 3.4% in 1993
to 5.5% (thus 3.5 million people) [2–4]. Recent epidemiologic
data from the ARNO observatory (a partnership between
the Italian Society of Diabetology and the Inter-University
Consortium ARNO Cineca) reported that 1 person out of
3 affected by DM is older than 65 years, and of these, 1
out of 4 is older than 75 years of age [2]. Less than 1% are
younger than 20 years and 3% are younger than 35 years [2].
The prevalence of DM is 6.1% in men and 5.5.% in women
with a consistent difference of 10% across all age groups
>35 years [2]. Currently 67% of patients are treated with
oral hypoglycemic drugs, 10% of them with a combination
with insulin and 11% with insulin alone [2]. It is estimated
that patients with type 1 diabetes mellitus (T1DM) represent
approximately 2-3%, whereas patients with type 2 diabetes
mellitus (T2DM) represent more than 90% of all patients
with known DM in Italy [5]. The Bruneck study (long-term,
prospective, population-based study in the town of Bruneck
located at the very north of Italy) reported an incidence rate
of 7.6 per 1,000 person-years of T2DM in individuals aged
40–79 years and independent risk factors for incident DM as
follows: impaired fasting glucose, overweight/obesity, insulin
resistance, and impaired insulin response to oral glucose [6].
In the province of Torino, the incidence rate of T1DM in
the age group of 30–49 years was 7.3 (6.2–8.6) per 100,000
person-years, being at least as high as that in the age group
of 15–19 years (6.8, 6.3–7.4) [7]. Men had two-fold higher
risk for developing T1DM than women in all age groups [7].
The incidence of known T2DMwas 50.7 per 100,000 person-
years in the age group of 30–49 years, representing the great
majority of new cases of DM [7]. The risk for developing
T2DM increased markedly with age, being seven-fold higher
in the age group of 40–49 years than in the age group of 30–
34 years, irrespective of sex [7]. The incidence of T1DM has
progressively increased in Italy with 3-4 times higher rates in
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Sardinia than in other parts of Italy [8, 9]. The Italian Health
Service system estimates that 10 billion euros is the annual
cost for the care of patients with DM, and these costs are
increasing over time [10, 11].
2. Diabetic Retinopathy: Global and Italian
Epidemiology Data
Diabetic retinopathy (DR) is the leading cause of legal
blindness among the working aged adults [12]. Nearly all the
patients with T1DM and the majority of those with T2DM
are affected by some form of DR after 20 years of disease
duration and 50%may develop sight-threatening DR [13–15].
Themain risk factors associated with an early onset and rapid
evolution of DR are duration of DM, poor glycemic control,
and presence of concomitant arterial hypertension [5]. The
Wisconsin Epidemiologic Study of Diabetic Retinopathy
(WESDR) reported that the incidence of diabetic macular
edema (DME) is 29% in T1DM over a period of 25 years and
25.4% among those with T2DM requiring insulin [13, 14, 16].
A pooled analysis from 35 studies worldwide (from 1980 to
2008) evaluating more than 20000 people with DM reported
an overall prevalence of any DR of 34.6% (95% confidence
interval) (CI, 34.5–34.8), proliferative DR (PDR) of 6.96%
(CI, 6.87–7.04), DME of 6.81% (CI, 6.74–6.89), and sight-
threatening DR of 10.2% (CI, 10.1–10.3) [17].
In Italy, there are no national data about prevalence
and incidence of legal blindness due to DR, and there is
no national registry of patients with DM [11]. However,
several studies reported the prevalence and incidence of DR
from geographically limited population-based studies [18–
20]. In one of these studies, 1321 patients with DM were
examined for DR in the Veneto Region (northeast of Italy).
DR prevalence was 26.2% (24.4% background DR and 1.8%
PDR) as reported in 1991 [18]. The prevalence of DR was
significantly related (𝑝 < 0.01) to the duration of DM
(17.3% for <5 years; 60.8% for >20 years) [18]. In the province
of Torino (northwest of Italy), DR was the second most
common cause of bilateral blindness (13.1%) in 4549 residents
who were certified blind between 1967 and 1991 [19]. Of
the 6857 consecutive patients seen between 1992 and 2003,
the prevalence of DR was 39% (19% mild nonproliferative
DR (NPDR), 11% moderate NPDR, and more severe in the
remaining cases) [21]. Furthermore, data collected by general
practitioners and diabetes specialists in Italy reported in 1997
that 13% of patients with diabetes had PDR and 2% suffered
from blindness [20].
In the province of Viterbo (located in the Lazio Region,
Central Italy) in 2002, DRwas the fourthmost frequent cause
of blindness accounting for 15% of cases [22]. When DM is
diagnosed after 30 years of age, the prevalence of DR is about
20% after 5 years, 40–50% after 10 years, and >90% after 20
years of disease [19]. The cumulative incidence of DR ranged
from34% to 59%during a four-year period, depending on the
age of patient and severity of disease [18, 19]. As a whole, DR
was responsible for 13% of cases of severe visual impairment
in Italy [18, 19].
Therefore, screening for DR remains crucial for early
diagnosis of the disease and preventing blindness and is
recommended in all patients with DM [23–25]. The “Asso-
ciazione Medici Diabetologi” (AMD), “Societa` Oftalmologica
Italiana,” “Societa` Italiana della Retina,” “Societa` Italiana di
Diabetologia,” and other organizations have jointly published
a guideline for the screening, diagnosis, and treatment of DR
in Italy, the “Linee-Guida Retinopatia Diabetica” [26].
However, screening for DR is delivered to only approx-
imately half of all patients with DM (as reported in the
United States), where the annual fundus examination was
recommended as the annual screening for DR [27, 28]. As a
consequence, the access to the treatment has been also limited
for these patients. The use of retinal photography with an
overall sensitivity of approximately 85% is considered cur-
rently the standard method to be used in a screening setting,
especially as it allows for implementation of telemedicine
programs [29–32].
3. Telemedicine Screening Programs in Italy
Data about the use of telemedicine for DR screening in Italy
are very limited in the literature. Vujosevic et al. underlined
the reliability of nonmydriatic techniques used in screening
and grading settings and confirmed the importance of digital
images over ophthalmoscopic examination in screening and
grading of DR [32]. These authors evaluated 3 nonmydriatic
field color fundus photos covering 45 degrees consisting in
field 1 (central), centered on the macula; field 2 (nasal),
centered on the nasal margin of the optic disc; and field
3 (temporal), centered superiorly and temporally from the
macula and compared to just one central fundus color photo
and to 7 standard stereoscopic 30-degree photos (ETDRS
fields) in detecting referable DR, defined as severe NPDR and
PDR and DME [32]. Sensitivity and specificity for detecting
referable DR were 82% and 92% and 83% and 97% for
referable DME for 3 nonmydriatic fields fundus photos and
significantly lower (below the requested target of the British
Diabetic Association necessary for an effective screening, set
at 80%) for one field fundus photo [32, 33].
In Torino the use of nonmydriatic fundus photos in the
screening program was introduced in 2000 [34]. The fundus
photos were taken in the diabetes center by trained nurses or
medical personnel and consist in 2 nonmydriatic 45-degree
color fundus photos, one centered on the macula/central
field and the other centered on the optic disc (nasal field)
as proposed by EURODIAB procedure [34, 35]. Grading
was performed by diabetes specialists, after specific training,
according to the EuropeanWorking Party recommendations
[34, 36]. Patients were assessed at retinal photography and
formally graded later. Feedback on referrals was by direct
discussion with the consultant ophthalmologists working in
the DR Centre. The authors evaluated the 6-year cumulative
incidence of referable DR and reported 10.5% (95% CI, 9.4–
11.8) [34]. Referable DR was considered in case of moderate
NPDR or worse (preproliferative DR, PDR, photocoagulated
DR, and advanced diabetic eye disease with or without mac-
ular involvement), equivalent to Early Treatment of Diabetic
Retinopathy Study (ETDRS) level >35 [37], whereas patients
with mild NPDR, equivalent to an ETDRS level ≤35, did not
require referral and were given rescreening appointments.
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Retinopathy progressed within 3 years to referable severity in
6.9% (95%CI, 4.3–11.0) of patientswith age at onset≥30 years,
who were on insulin treatment and had a known disease
duration of 10 years or longer. The other patients, especially
those with age at onset <30 years, on insulin and with a
duration <10 years, progressed more slowly [34].The authors
concluded that screening can be repeated safely at 2-year
intervals in any patient without DR [34].
The telematic screening program for DR in Padova area
(northeast of Italy) was systematically implemented for those
with DM in 2005 and since then a total of 17344 screening
exams of 9347 patients with DM have been performed
(data reported up to 2015). Color fundus photos of patients
with DM are acquired in two remote diabetes centers by
qualified staff (nurses or technicians) and thereafter sent
by dedicated intranet link to the Reading Centre, at the
Department of Ophthalmology of the University of Padova.
Images are acquired with the use of nonmydriatic fundus
cameras. The grading of images is performed by certified
medical personnel and confirmed by the responsible medical
retina specialist. In order to minimize errors, all evaluations
of images are performed in double grading fashion and in
case of discordance all adjudications are performed by the
experienced grader. The final grading report with the results
of DR grading is sent back electronically to the referring
Diabetes Clinic. Grading of images is based on the Inter-
national Diabetic Retinopathy and Macular Edema Severity
Scale [38]. The National Guidelines for Screening of DR
are adopted for determining the follow-up of patients [26].
Patients without DR or with mild NPDR are recommended
a reevaluation within 12 months in the screening service,
while patients with moderate NPDR are rescreened within
6–10 months and patients with severe NPDR or proliferative
DR or with any maculopathy are referred to the DR Clinic
for a complete ophthalmologic examination with possibility
to perform optical coherence tomography and fluorescein
angiography, if necessary. If grading is not certain or not
possible due to poor quality of images, a recommendation to
repeat either the screening examination or the ophthalmo-
logic evaluation is given (in 1.3% of cases). From 2005 to 2015,
the overall prevalence of DR in the city of Padova was 27.6%
consisting in 12.5%mild NPDR, 11.3%moderate NPDR, 2.9%
severe NPDR, and 0.9% proliferative DR (PDR) (manuscript
submitted). The overall prevalence of maculopathy was 5.7%
consisting in 2.8% mild, 2.2% moderate, and 0.7% severe
maculopathy. The 10-year incidence of sight-threating DR
(STDR) was 0.6% in patients with no DR, 5.5% in patients
with mild NPDR, and 21.1% in patients with moderate
NPDR at the first examination. The 10-year incidence of
maculopathy was 2.1% mild, 1.7% moderate, and 0.2% severe
maculopathy in patients with no maculopathy at the first
examination. When evaluating type and duration of DM
together, patients were divided into low risk, medium risk,
and high risk as follows: T2DM and duration lower than 10
years—low risk patients; T1DM and duration lower than 10
years—medium risk patients; and duration higher than 10
years and either T1DM or T2DM—high risk patients. The
best sensitivity/specificity ratio (94.4%/32.4%) was found at
2.5 years for low risk patients with noDR at first examination.
Therefore, the authors concluded that screening for DR can
be safely repeated in a two-and-a-half-year period in those
patients with diabetes who were deemed to be low risk dia-
betics. However, in case of presence of risk factors, amore fre-
quent follow-up regime is warranted (manuscript submitted).
Another pilot screening programwas recently performed
(2012) in Ponzano, a part of the Local Health Authorities of
Veneto Region, Treviso (northeast Italy), with participation
of a multidisciplinary group including general practitioners,
diabetes experts, administrative staff, nurses, epidemiologists
and ophthalmologists, and the reading centre [39]. This
project aimed to assess the feasibility of a future larger
application, in comparison with the “no prevention” strategy.
Screening for DR was based on 3 nonmydriatic, 45∘ field,
color fundus photos, obtained according to a previously
validated technique [32]. All photographs were obtained
by trained paramedical staff. All images were electronically
transmitted to the reading centre and stored in an on-line
secured database for the second step examination by certified
and expert graders from the Reading Centre, University
of Padova. Retinal images were graded for DR and DME
according to the International Classification proposed by the
American Academy of Ophthalmology [38]. When the qual-
ity of the images was “inadequate” for the clinical evaluation
and when fundus photographs were graded as “positive,”
these patients were referred for further ophthalmologic
examination. “Positive” findings included retinal changes
that required ophthalmologic management: moderate and
severe NPDR, proliferative DR, DME, or any other retinal
abnormality. A reportwith the results of the screening and the
correct follow-up timetable for the “negative” screened pop-
ulation was sent to the patient’s general practitioner within 1
month after the screening. The authors reported that a total
of 498 patients with diabetes were identified among the larger
sample and were invited for screening, with an attendance
rate of approximately 80%. Of these, 115 patients (33.82%)
were referred to an ophthalmologist, including patients with
ungradable images and cases with any abnormal retinal
findings, other than DR. Moreover, 9 cases required prompt
treatment for either PDR or DME. Significant importance
of screening program, also from an economic point of view,
was found, leading to a substantial saving in comparison with
the “no prevention” strategy, including the costs that avoid
blindness, in terms of the validity of the intervention and the
direct costs absorbed (efficiency) by the Regional Healthcare
Service (Veneto Region) [39].
In Milano, a recent observational study reported a 1-year
(2012-2013), single-center, remote evaluation of semiauto-
matic fundus photography for DR screening performed at
the Endocrinology Unit, during routine systemic visits for
patients with T2DM [40]. A total of 1281 adults with T2DM
underwent fundus photos consisting in three 30-degree fields
color fundus photos (central, nasal, and temporal) obtained
before and after pupil dilation and thereafter assessed by 2
expert ophthalmologists who were blinded to the results of
the slit-lamp fundus examination. After pupil dilation 240
patients (18.74%) had ungradable images; approximately two
thirds of patients (823 patients) did not have DR, and 218
(17.01%) were diagnosed with DR. Consequently, a total of
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458 (35.75%) patients (240 ungradable and 218 with DR)
were referred to the ophthalmologist. The authors evaluated
also the economic impact of the telematic screening and
reported a significant cost saving compared to slit-lamp
fundus examination (the evaluated costs included reading
centre staff evaluating images, fundus camera, and the cost
of the standard funduscopic examination) [40].
Although initially annual screening for DR was recom-
mended by many professional societies and was practiced
in many countries, currently there is an increasing evi-
dence of cost-effectiveness studies that suggest that screening
could be safely extended beyond one year in patients with
T2DM at low risk of progression to DR (considered to be
patients with well controlled DM on dietary treatment, with
low HbA1c and no DR), without increased risk of vision
loss [41]. Biennial screening showed long safety record in
Iceland and Sweden [42, 43]. Moreover, adopting biennial
screening approach, a reduction in approximately 25% of
screening costs can be obtained without increased risk to the
patient [44]. Two recent studies reported cost-effectiveness
of adopting risk-stratified approaches to extended screening
intervals in the national DR screening programs in England
and Scotland [45, 46]. Scanlon et al. conducted a modelling
study and reported that for patients without DR on two
consecutive screening examinations the adoption of 2-year
screening intervals would save on average 225000 pounds
per QUALY (quality-adjusted life years) lost compared with
annual screening in England [45]. Scotland et al. reported
similar results for patients with T2DM and lower increment
in cost-effectiveness ratios for patients with T1DM (85000
pounds) per QUALY gained [46].
4. Conclusions
DR is a relevant and significant complication of DM and
affects a large number of patients, with significant costs for
the Health System. Prevention of DR through reducing risk
factors and screening (early diagnosis) results in preventing
visual impairment. Telematic screening for DR has been
implemented with success in several local health entities in
Italy, demonstrating good interdisciplinary collaboration and
patient satisfaction. Moreover, with recent reports [45–49]
on possibility to effectively increase screening intervals in
patients with no DR and at low risk for developing sight-
threating DR, the screening program becomes even more
cost-effective procedure with appropriate use of resources
and safe care delivered for patients. The preliminary data
already present in the literature together with already avail-
able local experience in DR screeningmay become a basis for
developing a national screening program.
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